オートインジェクター市場規模、シェア、動向、2031年までの世界予測

世界のオートインジェクター市場は、2026年の1,273億米ドルから2031年には3,004億6,000万米ドルに成長し、予測期間中の年平均成長率は18.7%に達するとMarketsandMarketsでは予測しています。

慢性疾患や自己免疫疾患の罹患率の上昇、そして世界人口の増加を背景に、オートインジェクターの需要は着実に伸びています。長期治療におけるオートインジェクターの普及拡大と、在宅医療への移行が、製品利用を促進しています。患者は、正確な薬剤投与と安全性を確保するため、高品質で安全かつ使いやすいオートインジェクターを求めています。針なしオートインジェクター、スマートコネクテッドデバイス、内蔵センサーなどの技術革新も、市場への普及をさらに加速させています。加えて、新興国における医療インフラの拡充と、現代医療を推進する政府の支援策も、今後数年間の力強い市場成長を支えると予想されます。

調査概要

本レポートは、オートインジェクター市場を、タイプ、用途、作動機構、投与経路、治療領域、薬剤の種類、販売量、エンドユーザー、地域別に分析しています。また、市場成長に影響を与える要因、様々な機会と課題、そして市場リーダーの競争環境についても詳細に解説しています。さらに、個々の成長傾向に基づいてマイクロ市場を分析し、5つの主要地域（および各地域内の各国）における市場セグメントの収益予測を提供しています。

本レポートを購入する理由

本レポートは、既存企業と中小企業の両方が市場をより深く理解するのに役立ち、ひいては市場シェアの拡大に貢献します。本レポートを購入した企業は、以下の戦略のいずれか、または複数の戦略を組み合わせて活用することで、市場における地位を強化することができます。

本レポートは、以下のポイントに関する洞察を提供します。

オートインジェクター市場の成長に影響を与える主要な推進要因（慢性疾患の罹患率の上昇、規制当局の承認件数の増加、バイオシミラーおよびバイオ医薬品への高い需要、自己投与薬の普及拡大、政府支援および有利な償還政策）、阻害要因（針を使わない薬剤投与システムへの注力、注射針恐怖症の蔓延）、機会（生物学的分子の特許期限切れ、技術的に高度なオートインジェクターの発売、新興市場における未開拓の機会）、および課題（複数の薬剤粘度に対応するオートインジェクターの開発、機器の誤作動およびリコールのリスク）の分析

• 市場浸透：オートインジェクター市場における主要企業が提供する製品ポートフォリオに関する包括的な情報
• 製品開発／イノベーション：オートインジェクター市場における今後のトレンド、研究開発活動、および製品開発に関する詳細な洞察
• 市場開発：有望な新興地域に関する包括的な情報
• 市場多様化：オートインジェクター市場における新製品、成長地域、最新動向に関する包括的な情報
• 競合分析：主要市場プレーヤーの市場セグメント、成長戦略、収益分析、製品に関する詳細な分析

Report Description

The global autoinjectors market is projected to reach USD 300.46 billion by 2031 from USD 127.30 billion in 2026, at a CAGR of 18.7% during the forecast period.

The demand for autoinjectors is experiencing steady growth, fueled by the increasing prevalence of chronic and autoimmune diseases and the growing global population. The rising adoption of autoinjectors for long-term treatments, along with the shift toward home-based care, is boosting product use. Patients are seeking high-quality, safe, and easy-to-use autoinjectors to ensure accurate drug delivery and safety. Technological advances such as needle-free autoinjectors, smart connected devices, and built-in sensors are further increasing market adoption. Additionally, expanding healthcare infrastructure in emerging economies and supportive government initiatives promoting modern healthcare are expected to maintain strong market growth in the coming years.

“By drug type, the biologics segment is projected to capture a significant market share.”

Based on drug type, biologics are the dominant segment in the autoinjectors market, driven by their increased use in treating chronic and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and diabetes. Furthermore, growing investments in biotechnology and biosimilar development, along with increasing regulatory approvals for biologics, are further boosting demand. Many biologics require parenteral administration, making them compatible with autoinjectors. The expanding pipeline of monoclonal antibodies and other biologic injectables is also accelerating demand.

“By route of administration, the subcutaneous route of administration segment is expected to register the largest share in 2025.”

By route of administration, the subcutaneous route holds the largest share in the autoinjectors market because it allows drugs to be delivered with less pain than the intramuscular route, due to reduced penetration depth. The subcutaneous route is favored for biologic therapies because it provides consistent drug absorption and better patient compliance. The increasing prevalence of chronic and acute diseases, along with more hospital admissions, continues to boost demand for long-term treatments, which further increases the demand for autoinjectors.

In 2025, North America accounted for the largest share of the autoinjectors market by region.

The autoinjectors market is divided into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. North America dominates the global autoinjectors market; this leadership is due to the high prevalence of chronic diseases, an established healthcare infrastructure, and rapid adoption of advanced medical technologies. Moreover, the strong presence of key market players, increased healthcare spending, and rising demand for advanced infusion systems in hospitals and home healthcare settings all support the region’s dominant market position.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–40%, Tier 2–35%, and Tier 3– 25%
• By Designation: Directors–23%, Managers–30%, and Others–47%
• By Region: North America–25%, Europe–35%, Asia Pacific–20%, Latin America- 13%, and the Middle East & Africa- 7%

The prominent players in the autoinjector devices market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). However, prominent players in the autoinjector finished formulation market include Novo Nordisk (Denmark), Eli Lilly and Company (US), and AbbVie (US).

Research Coverage

This report examines the autoinjectors market based on type, usage, actuation mechanism, route of administration, therapy area, drug type, volume, end user, and region. It also discusses the factors influencing market growth, analyzes various opportunities and challenges, and provides details about the competitive landscape for market leaders. Additionally, the report analyzes micro markets in terms of their individual growth trends and forecasts the revenue of market segments across five main regions (and the respective countries within these regions).

Reasons to Buy the Report

The report will help both established and smaller firms understand the market better, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies below to strengthen their market position.

This report provides insights into the following pointers:

Analysis of key drivers (rising prevalence of chronic diseases, Increasing regulatory approvals, high demand for biosimilars and biologics, growing adoption of self-administered medicines, government support and favorable reimbursement policies), restraints (focus on needle-free drug delivery systems and prevalence of needle phobia), opportunities (impending patent expiry of biological molecules, launch of technologically advanced autoinjectors, untapped opportunities in emerging markets), and challenges (development of autoinjectors for multiple drug viscosities, risk of device  malfunctions and recalls) influencing the growth of autoinjectors market

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the autoinjectors market
• Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product developments in the autoinjectors market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the autoinjectors market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

Table of Contents

1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.3 STUDY SCOPE 49
1.3.1 SEGMENTS CONSIDERED 49
1.3.2 INCLUSIONS & EXCLUSIONS 50
1.3.3 YEARS CONSIDERED 51
1.3.4 CURRENCY CONSIDERED 51
1.4 STAKEHOLDERS 52
1.5 SUMMARY OF CHANGES 52
2 EXECUTIVE SUMMARY 54
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 54
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 56
2.3 DISRUPTIVE TRENDS IN AUTOINJECTORS MARKET 58
2.4 HIGH-GROWTH SEGMENTS 58
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 60
3 PREMIUM INSIGHTS 62
3.1 AUTOINJECTORS MARKET OVERVIEW 62
3.2 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY AND USAGE 63
3.3 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY AND ACTUATION MECHANISM 64
3.4 GEOGRAPHIC SNAPSHOT OF AUTOINJECTOR DEVICES MARKET 65
3.5 GEOGRAPHIC SNAPSHOT OF FINISHED FORMULATION AUTOINJECTORS MARKET 66
4 MARKET OVERVIEW 67
4.1 INTRODUCTION 67
4.2 MARKET DYNAMICS 67
4.2.1 DRIVERS 68
4.2.1.1 Rising prevalence of chronic and autoimmune diseases 68
4.2.1.2 Increasing regulatory approvals for autoinjectors 68
4.2.1.3 High demand for biosimilars and biologics 69
4.2.1.4 Growing adoption of self-administered medicines 70
4.2.1.5 Government support and favorable reimbursement policies 71
4.2.2 RESTRAINTS 72
4.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia 72

4.2.3 OPPORTUNITIES 72
4.2.3.1 Impending patent expiry of biological molecules 72
4.2.3.2 Launch of technologically advanced autoinjectors 74
4.2.3.3 Untapped opportunities in emerging markets 74
4.2.4 CHALLENGES 75
4.2.4.1 Development of autoinjectors for multiple drug viscosities 75
4.2.4.2 Risk of device malfunctions and recalls 75
4.3 UNMET NEEDS AND WHITE SPACES 75
4.3.1 UNMET NEEDS IN AUTOINJECTORS MARKET 75
4.3.2 WHITE SPACE OPPORTUNITIES 76
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 76
4.4.1 INTERCONNECTED MARKETS 76
4.4.2 CROSS-SECTOR OPPORTUNITIES 77
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 77
5 INDUSTRY TRENDS 79
5.1 PORTER’S FIVE FORCES ANALYSIS 79
5.1.1 THREAT OF NEW ENTRANTS 80
5.1.2 THREAT OF SUBSTITUTES 80
5.1.3 BARGAINING POWER OF SUPPLIERS 81
5.1.4 BARGAINING POWER OF BUYERS 81
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.2 MACROECONOMIC OUTLOOK 82
5.2.1 INTRODUCTION 82
5.2.2 GDP TRENDS AND FORECAST 82
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 83
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 83
5.3 SUPPLY CHAIN ANALYSIS 84
5.4 VALUE CHAIN ANALYSIS 85
5.5 MARKET ECOSYSTEM 86
5.5.1 AUTOINJECTORS MARKET PROVIDERS 86
5.5.2 END USERS 88
5.5.3 REGULATORY BODIES 88
5.6 PRICING ANALYSIS 89
5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER, 2025 (USD) 89
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD) 90
5.6.2.1 Rheumatoid arthritis 90
5.6.2.2 Anaphylaxis 90
5.6.2.3 Diabetes 90
5.6.2.4 Obesity 91

5.7 TRADE ANALYSIS 92
5.7.1 IMPORT DATA FOR HS CODE 901890 92
5.7.2 EXPORT DATA FOR HS CODE 901890 93
5.8 REIMBURSEMENT SCENARIO 93
5.8.1 KEY CONFERENCES & EVENTS (2025–2026) 94
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 95
5.10 INVESTMENT & FUNDING SCENARIO 96
5.11 CASE STUDY ANALYSIS 97
5.12 IMPACT OF US TARIFFS—AUTOINJECTORS MARKET 98
5.12.1 INTRODUCTION 98
5.12.2 KEY TARIFF RATES 99
5.12.3 PRICE IMPACT ANALYSIS 99
5.12.4 IMPACT ON COUNTRIES/REGIONS 100
5.12.4.1 North America 100
5.12.4.2 Asia Pacific 100
5.12.4.3 Europe 101
5.12.4.4 Latin America 102
5.12.5 IMPACT ON END-USE SEGMENTS 102
5.13 DEVICES FOR LARGE-VOLUME FORMULATIONS 103
5.14 DEVICES FOR HIGHLY VISCOUS FORMULATIONS 103
5.15 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET 106
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 107
6.1 KEY EMERGING TECHNOLOGIES 107
6.1.1 INJECTION MECHANISM TECHNOLOGY 107
6.1.2 ELECTRONIC AND CONNECTIVITY SOLUTIONS 107
6.2 COMPLEMENTARY TECHNOLOGIES 108
6.2.1 POWER ASSISTANCE MECHANISMS 108
6.2.2 ADVANCED NEEDLE TECHNOLOGY 108
6.2.3 DRUG CONTAINER AND CARTRIDGE TECHNOLOGIES 109
6.3 ADJACENT TECHNOLOGIES 109
6.3.1 WEARABLE DRUG DELIVERY DEVICES 109
6.3.2 IMPLANTABLE DRUG DELIVERY SYSTEMS 109
6.3.3 NEEDLE-FREE INJECTION TECHNOLOGY 110
6.4 TECHNOLOGY/PRODUCT ROADMAP 110
6.4.1 NEAR TERM (2025-2027) 110
6.4.2 MID-TERM (2028-2030) 110
6.4.3 LONG TERM (2030+) 111
6.5 PATENT ANALYSIS 111
6.5.1 JURISDICTION AND TOP APPLICANT ANALYSIS 111
6.6 FUTURE APPLICATIONS 115
6.6.1 AI-ENABLED PERSONALIZED DRUG DELIVERY 115
6.6.2 COMBINATION THERAPY DELIVERY 115
6.6.3 REUSABLE AUTOINJECTOR PLATFORMS 116
6.7 IMPACT OF AI/GEN AI ON AUTOINJECTORS MARKET 116
6.7.1 INTRODUCTION 116
6.7.2 TOP USE CASES AND MARKET POTENTIAL 116
6.7.3 BEST PRACTICES FOLLOWED BY MANUFACTURERS/OEMS IN AUTOINJECTORS MARKET 118
7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 120
7.1 DECISION-MAKING PROCESS 120
7.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 120
7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 121
7.2.2 BUYING CRITERIA 122
7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 123
7.4 UNMET NEEDS OF VARIOUS END-USE INDUSTRIES 123
7.5 MARKET PROFITABILITY 124
8 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 125
8.1 REGIONAL REGULATIONS AND COMPLIANCE 125
8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125
8.1.2 REGULATORY FRAMEWORK 127
8.1.2.1 North America 127
8.1.2.2 Europe 128
8.1.2.3 Asia Pacific 128
8.1.2.4 Latin America 129
8.1.2.5 Middle East & Africa 129
8.1.3 CERTIFICATIONS, LABELING, ECO-STANDARDS 129
8.1.4 INDUSTRY STANDARDS 129
8.2 SUSTAINABILITY INITIATIVES 130
8.2.1 REUSABLE AUTOINJECTOR PLATFORMS 130
8.2.2 USE OF BIO-BASED POLYMERS 130
8.2.3 CIRCULAR DEVICE DESIGN AND RECYCLABILITY 130
9 AUTOINJECTORS MARKET, BY TYPE 131
9.1 INTRODUCTION 132
9.2 FINISHED FORMULATION AUTOINJECTORS 132
9.2.1 READY-TO-USE DESIGN AND PATIENT CONVENIENCE DRIVE MARKET LEADERSHIP 132

9.3 AUTOINJECTOR DEVICES 134
9.3.1 FLEXIBILITY AND PLATFORM-BASED INTEGRATION SUPPORT MARKET ADOPTION 134
10 AUTOINJECTORS MARKET, BY USAGE 136
10.1 INTRODUCTION 137
10.2 DISPOSABLE AUTOINJECTORS 138
10.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH 138
10.3 REUSABLE AUTOINJECTORS 141
10.3.1 COST-EFFECTIVENESS, ADAPTABILITY, AND SUSTAINABILITY TO DRIVE MARKET EXPANSION 141
11 AUTOINJECTORS MARKET, BY ACTUATION MECHANISM 144
11.1 INTRODUCTION 145
11.2 MECHANICAL (SPRING-BASED) AUTOINJECTORS 146
11.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH 146
11.3 ELECTRONIC AUTOINJECTORS 149
11.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH 149
12 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION 152
12.1 INTRODUCTION 153
12.2 SUBCUTANEOUS ADMINISTRATION 154
12.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH 154
12.3 INTRAMUSCULAR ADMINISTRATION 157
12.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET 157
13 AUTOINJECTORS MARKET, BY THERAPY AREA 160
13.1 INTRODUCTION 161
13.2 RHEUMATOID ARTHRITIS 162
13.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET 162
13.3 DIABETES 164
13.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND 164
13.4 ANAPHYLAXIS 166
13.4.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH 166
13.5 MULTIPLE SCLEROSIS 167
13.5.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH 167

13.6 OBESITY 169
13.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH 169
13.7 OTHER THERAPY AREAS 170
14 AUTOINJECTORS MARKET, BY DRUG TYPE 172
14.1 INTRODUCTION 173
14.2 BIOLOGICS 174
14.2.1 INCREASING USE IN INJECTABLE THERAPIES AND SELF-ADMINISTRATION TO DRIVE MARKET 174
14.3 BIOSIMILARS 177
14.3.1 COST-EFFECTIVE ALTERNATIVES ACCELERATING MARKET EXPANSION 177
14.4 SMALL MOLECULES 180
14.4.1 CRITICAL ROLE IN SELECTIVE INJECTABLES AND EMERGENCY USE CASES 180
15 AUTOINJECTORS MARKET, BY VOLUME 183
15.1 INTRODUCTION 184
15.2 UP TO 3ML 185
15.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH 185
15.3 ABOVE 3ML 188
15.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE THE MARKET 188
16 AUTOINJECTORS MARKET, BY END USER 191
16.1 AUTOINJECTOR DEVICE END USERS 192
16.1.1 PHARMACEUTICAL & BIOTECH COMPANIES 192
16.1.1.1 Expanding pipelines, advancements, and rising patient adherence to propel market 192
16.1.2 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 194
16.1.2.1 Growing trend of outsourcing and demand for specialized drug-device manufacturing capabilities support growth 194
16.2 FINISHED FORMULATION AUTOINJECTOR END USERS 195
16.2.1 HOME CARE SETTINGS 195
16.2.1.1 Cost-effectiveness and increased availability of home care support services to propel market growth 195
16.2.2 HOSPITALS & CLINICS 197
16.2.2.1 Technological advancements and availability of real-time patient data to support market growth 197
16.2.3 AMBULATORY CARE CENTERS 198
16.2.3.1 Growing demand for outpatient services to fuel market growth 198
16.2.4 OTHER END USERS 199

17 AUTOINJECTORS MARKET, BY REGION 201
17.1 INTRODUCTION 202
17.2 NORTH AMERICA 203
17.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 203
17.2.2 US 213
17.2.2.1 US holds largest share in North American 213
17.2.3 CANADA 219
17.2.3.1 Aging population and increasing prevalence of allergies to propel market growth 219
17.3 EUROPE 224
17.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 224
17.3.2 GERMANY 232
17.3.2.1 Growing investments and increasing government spending on healthcare to drive market 232
17.3.3 UK 238
17.3.3.1 Increase in prevalence of lifestyle diseases and allergies supports demand growth 238
17.3.4 FRANCE 243
17.3.4.1 Favorable reimbursement policies and increased investment to drive market growth 243
17.3.5 ITALY 249
17.3.5.1 Rising elderly population pool to drive the market 249
17.3.6 SPAIN 254
17.3.6.1 Favorable reimbursement scenario and prevalence of chronic disease 254
17.3.7 NETHERLANDS 260
17.3.7.1 Strong healthcare system and aging population drive market growth 260
17.3.8 REST OF EUROPE 265
17.4 ASIA PACIFIC 270
17.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 270
17.4.2 JAPAN 280
17.4.2.1 High healthcare expenditure, favorable reimbursement, and insurance coverage to support market growth 280
17.4.3 CHINA 286
17.4.3.1 Increase in prevalence of lifestyle diseases and allergies drives market growth 286
17.4.4 INDIA 291
17.4.4.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth 291
17.4.5 AUSTRALIA 297
17.4.5.1 Growing older population and rising prevalence of target diseases to propel market 297
17.4.6 SOUTH KOREA 302
17.4.6.1 Rising obesity and chronic disease burden propel market growth 302
17.4.7 THAILAND 307
17.4.7.1 Rising geriatric population and chronic disease burden driving autoinjectors market growth 307
17.4.8 VIETNAM 313
17.4.8.1 Aging population and healthcare expansion aiding autoinjectors market growth in Vietnam 313
17.4.9 REST OF ASIA PACIFIC 318
17.5 LATIN AMERICA 323
17.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 323
17.5.2 BRAZIL 331
17.5.2.1 Rising obesity to stimulate market growth 331
17.5.3 MEXICO 336
17.5.3.1 Rising disease burden to support market growth 336
17.5.4 REST OF LATIN AMERICA 342
17.6 MIDDLE EAST & AFRICA 347
17.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 347
17.6.2 GCC COUNTRIES 355
17.6.2.1 Kingdom of Saudi Arabia (KSA) 361
17.6.2.1.1 Strong public investments and rising trend of home care to propel market 361
17.6.2.2 United Arab Emirates 367
17.6.2.2.1 Favorable government strategies for health and infrastructure driving market growth 367
17.6.2.3 Other GCC Countries 372
17.6.3 REST OF MIDDLE EAST & AFRICA 377
18 COMPETITIVE LANDSCAPE 383
18.1 INTRODUCTION 383
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2026 383
18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET 384
18.3 REVENUE ANALYSIS, 2023–2025 388
18.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET 388
18.3.2 REVENUE ANALYSIS: FINISHED FORMULATION AUTOINJECTORS MARKET 389
18.4 MARKET SHARE ANALYSIS, 2025 389
18.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET 389
18.4.2 MARKET SHARE ANALYSIS: FINISHED FORMULATION AUTOINJECTORS MARKET 392
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 395
18.5.1 AUTOINJECTOR DEVICES MARKET 395
18.5.1.1 Stars 395
18.5.1.2 Emerging leaders 395
18.5.1.3 Pervasive players 395
18.5.1.4 Participants 396
18.5.1.5 Company footprint: key players, 2025 397
18.5.1.5.1 Company footprint 397
18.5.1.5.2 Region footprint 398
18.5.1.5.3 Usage footprint 399
18.5.1.5.4 Volume footprint 400
18.5.1.5.5 Route of administration footprint 401
18.5.2 FINISHED FORMULATION AUTOINJECTORS MARKET 402
18.5.2.1 Stars 402
18.5.2.2 Emerging leaders 402
18.5.2.3 Pervasive players 402
18.5.2.4 Participants 402
18.5.2.5 Company footprint: key players, 2025 404
18.5.2.5.1 Company footprint 404
18.5.2.5.2 Region footprint 404
18.5.2.5.3 Usage footprint 405
18.5.2.5.4 Volume footprint 405
18.5.2.5.5 Route of administration footprint 406
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 406
18.6.1 AUTOINJECTOR DEVICES MARKET 406
18.6.1.1 Progressive companies 406
18.6.1.2 Responsive companies 406
18.6.1.3 Dynamic companies 406
18.6.1.4 Starting blocks 406
18.6.1.5 Competitive benchmarking: Startups/SMEs, 2025 408
18.6.1.6 Competitive benchmarking of key startup/SME players 409
18.6.2 FINISHED FORMULATION AUTOINJECTORS MARKET 409
18.6.2.1 Progressive companies 409
18.6.2.2 Responsive companies 409
18.6.2.3 Dynamic companies 409
18.6.2.4 Starting blocks 409
18.6.2.5 Competitive benchmarking: startups/SMEs, 2025 411
18.6.2.6 Competitive benchmarking of key startup/SME players 411
18.7 COMPANY VALUATION AND FINANCIAL METRICS 412
18.7.1 FINANCIAL METRICS 412
18.7.2 COMPANY VALUATION 412
18.8 BRAND COMPARISON 413
18.9 COMPETITIVE SCENARIO 414
18.9.1 PRODUCT LAUNCHES & APPROVALS 414
18.9.2 DEALS 415
18.9.3 EXPANSIONS 416
18.9.4 PRODUCT LAUNCHES & APPROVALS 416
18.9.5 DEALS 418
18.9.6 EXPANSIONS 418
19 COMPANY PROFILES 419
19.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET 419
19.1.1 SHL MEDICAL AG 419
19.1.1.1 Business overview 419
19.1.1.2 Products offered 419
19.1.1.3 Recent developments 420
19.1.1.3.1 Product launches 420
19.1.1.3.2 Deals 421
19.1.1.3.3 Expansions 423
19.1.1.4 MnM view 423
19.1.1.4.1 Key strengths 423
19.1.1.4.2 Strategic choices 424
19.1.1.4.3 Weaknesses and competitive threats 424
19.1.2 YPSOMED AG 425
19.1.2.1 Business overview 425
19.1.2.2 Products offered 427
19.1.2.3 Recent developments 428
19.1.2.3.1 Product launches 428
19.1.2.3.2 Deals 428
19.1.2.3.3 Expansions 430
19.1.2.4 MnM view 430
19.1.2.4.1 Key strengths 430
19.1.2.4.2 Strategic choices 430
19.1.2.4.3 Weaknesses and competitive threats 431
19.1.3 WEST PHARMACEUTICAL SERVICES, INC. 432
19.1.3.1 Business overview 432
19.1.3.2 Products offered 433
19.1.3.3 Recent developments 434
19.1.3.3.1 Expansions 434
19.1.3.4 MnM view 434
19.1.3.4.1 Key strengths 434
19.1.3.4.2 Strategic choices 434
19.1.3.4.3 Weaknesses and competitive threats 434
19.1.4 BECTON, DICKINSON AND COMPANY (BD) 435
19.1.4.1 Business overview 435
19.1.4.2 Products offered 436
19.1.4.3 Recent developments 437
19.1.4.3.1 Deals 437
19.1.4.4 MnM view 437
19.1.4.4.1 Key strengths 437
19.1.4.4.2 Strategic choices 437
19.1.4.4.3 Weaknesses and competitive threats 438
19.1.5 PHILLIPS-MEDISIZE 439
19.1.5.1 Business overview 439
19.1.5.2 Products offered 439
19.1.5.3 Recent developments 440
19.1.5.3.1 Expansions 440
19.1.6 HALOZYME, INC. 441
19.1.6.1 Business overview 441
19.1.6.2 Products offered 442
19.1.7 OWEN MUMFORD 443
19.1.7.1 Business overview 443
19.1.7.2 Products offered 443
19.1.7.3 Recent developments 444
19.1.7.3.1 Product launches 444
19.1.7.3.2 Deals 444
19.2 KEY PLAYERS: FINISHED FORMULATION AUTOINJECTORS MARKET 445
19.2.1 ELI LILLY AND COMPANY 445
19.2.1.1 Business overview 445
19.2.1.2 Products offered 446
19.2.1.3 Recent developments 447
19.2.1.3.1 Product approvals 447
19.2.1.3.2 Deals 448
19.2.1.3.3 Expansions 449
19.2.1.4 MnM view 450
19.2.1.4.1 Key strengths 450
19.2.1.4.2 Strategic choices 450
19.2.1.4.3 Weaknesses and competitive threats 450
19.2.2 ABBVIE INC. 451
19.2.2.1 Business overview 451
19.2.2.2 Products offered 452
19.2.2.3 Recent developments 453
19.2.2.3.1 Product approvals 453
19.2.2.3.2 Deals 454
19.2.2.4 MnM view 454
19.2.2.4.1 Key strengths 454
19.2.2.4.2 Strategic choices 454
19.2.2.4.3 Weaknesses and competitive threats 454
19.2.3 SANOFI 455
19.2.3.1 Business overview 455
19.2.3.2 Products offered 456
19.2.3.3 Recent developments 457
19.2.3.3.1 Product approvals 457
19.2.3.4 MnM view 457
19.2.3.4.1 Key strengths 457
19.2.3.4.2 Strategic choices 457
19.2.3.4.3 Weaknesses and competitive threats 457
19.2.4 NOVO NORDISK A/S 458
19.2.4.1 Business overview 458
19.2.4.2 Products offered 459
19.2.4.3 Recent developments 460
19.2.4.3.1 Product approvals 460
19.2.4.3.2 Deals 461
19.2.4.3.3 Expansions 461
19.2.4.3.4 Other developments 462
19.2.5 AMGEN INC. 463
19.2.5.1 Business overview 463
19.2.5.2 Products offered 464
19.2.5.3 Recent developments 465
19.2.5.3.1 Product launches 465
19.2.5.3.2 Expansions 466
19.2.5.3.3 Other developments 466
19.2.6 JOHNSON & JOHNSON 467
19.2.6.1 Business overview 467
19.2.6.2 Products offered 468
19.2.6.3 Recent developments 469
19.2.6.3.1 Product approvals 469
19.2.6.3.2 Other developments 469
19.2.7 GSK PLC 470
19.2.7.1 Business overview 470
19.2.7.2 Products offered 471
19.2.7.3 Recent developments 472
19.2.7.3.1 Product approvals 472
19.2.8 ASTRAZENECA 473
19.2.8.1 Business overview 473
19.2.8.2 Products offered 474
19.2.8.3 Recent developments 475
19.2.8.3.1 Product approvals 475
19.2.8.3.2 Deals 475
19.2.8.3.3 Expansions 476
19.2.8.3.4 Other developments 476

19.3 OTHER PLAYERS 477
19.3.1 GERRESHEIMER AG 477
19.3.2 HASELMEIER GMBH 477
19.3.3 SMC LTD 478
19.3.4 KALEO, INC. 478
19.3.5 SOLTEAM INCORPORATION CO., LTD. 479
19.3.6 ELCAM DRUG DELIVERY DEVICES 480
19.3.7 CROSSJECT 481
19.3.8 JABIL, INC. 481
19.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC 482
19.3.10 MIDAS PHARMA GMBH 482
19.3.11 XERIS PHARMACEUTICALS, INC. 483
19.3.12 WINDGAP MEDICAL, INC 483
19.3.13 ALTAVIZ 484
20 RESEARCH METHODOLOGY 485
20.1 RESEARCH DATA 485
20.2 RESEARCH METHODOLOGY DESIGN 485
20.2.1 SECONDARY DATA 486
20.2.1.1 Key data from secondary sources 487
20.2.2 PRIMARY DATA 488
20.2.2.1 Key industry insights 489
20.3 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES 491
20.4 MARKET SIZE ESTIMATION: FINISHED FORMULATIONS 493
20.4.1 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 496
20.5 MARKET GROWTH RATE PROJECTIONS 497
20.6 DATA TRIANGULATION 500
20.7 MARKET SHARE ANALYSIS 501
20.8 RESEARCH ASSUMPTIONS 501
20.8.1 GROWTH RATE ASSUMPTIONS 502
20.9 RISK ASSESSMENT 503
20.10 LIMITATIONS 503
20.10.1 METHODOLOGY-RELATED LIMITATIONS 503
20.10.2 SCOPE-RELATED LIMITATIONS 503
20.11 RISK ANALYSIS 504

21 APPENDIX 505
21.1 DISCUSSION GUIDE 505
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 514
21.3 CUSTOMIZATION OPTIONS 516
21.3.1 COMPANY INFORMATION 516
21.3.2 GEOGRAPHIC ANALYSIS 516
21.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 516
21.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 516
21.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 516
21.4 RELATED REPORTS 517
21.5 AUTHOR DETAILS 518

LIST OF TABLES

TABLE 1 AUTOINJECTORS MARKET: INCLUSIONS & EXCLUSIONS 50
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 51
TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS, 2023–2025 69
TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS 73
TABLE 5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS IN AUTOINJECTOR DEVICES MARKET 77
TABLE 6 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 79
TABLE 7 GDP CHANGE, BY KEY COUNTRIES, 2021-2030, IN USD BILLION 82
TABLE 8 LIST OF KEY AUTOINJECTOR DEVICE PROVIDERS 87
TABLE 9 LIST OF KEY FINISHED FORMULATION PRODUCT PROVIDERS 87
TABLE 10 LIST OF KEY END USERS 88
TABLE 11 LIST OF KEY REGULATORY BODIES 88
TABLE 12 AVERAGE SELLING PRICE OF FINISHED FORMULATION AUTOINJECTORS,
BY KEY PLAYER, 2025 (USD) 89
TABLE 13 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR RHEUMATOID ARTHRITIS, BY REGION, 2023–2025 (USD) 90
TABLE 14 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR ANAPHYLAXIS, BY REGION, 2023–2025 (USD) 90
TABLE 15 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR DIABETES, BY REGION, 2023–2025 (USD) 90
TABLE 16 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR OBESITY BY REGION, 2023–2025 (USD) 91
TABLE 17 AVERAGE SELLING PRICE OF 0F AUTOINJECTOR DEVICES FOR DISPOSABLE AND REUSABLE AUTOINJECTORS, BY KEY PLAYER, 2025 (USD) 91
TABLE 18 AVERAGE SELLING PRICE TREND 0F DISPOSABLE AUTOINJECTORS, BY REGION, 2023–2025, (USD) 92
TABLE 19 AVERAGE SELLING PRICE TREND 0F REUSABLE AUTOINJECTORS, BY REGION, 2023–2025, (USD) 92
TABLE 20 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL,
SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY,
2021–2025 (USD THOUSAND) 92
TABLE 21 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL,
SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY,
2021–2025 (USD THOUSAND) 93
TABLE 22 AUTOINJECTORS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 94
TABLE 23 CASE STUDY 1: MERCK KGAA’S REBISMART SMART MEDICATION MANAGEMENT 97
TABLE 24 CASE STUDY 2: USB’S CIMZIA AUTOCLICKS ENHANCING
AUTOINJECTORS USABILITY 97
TABLE 25 CASE STUDY 3: PRODUCT DEVELOPMENT SUPPORT
FOR REUSABLE AUTOINJECTORS 98
TABLE 26 US ADJUSTED RECIPROCAL TARIFF RATES, 2024 99
TABLE 27 KEY PRODUCT-RELATED TARIFF EFFECTIVE 99
TABLE 28 NORTH AMERICA: IMPACT OF US TARIFF ON CANADA 100
TABLE 29 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 100
TABLE 30 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 101
TABLE 31 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 102
TABLE 32 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS 103
TABLE 33 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS 104
TABLE 34 FORMULATION AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS
DELIVERY OF HIGH-DOSE BIOLOGICS 104
TABLE 35 AUTOINJECTORS MARKET: KEY PATENTS, 2023–2025 113
TABLE 36 BEST PRACTICES FOLLOWED BY MANUFACTURERS/OEMS 119
TABLE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF AUTOINJECTORS 121
TABLE 38 KEY BUYING CRITERIA FOR AUTOINJECTORS, BY END USER 122
TABLE 39 ADOPTION BARRIERS & INTERNAL CHALLENGES IN AUTOINJECTORS MARKET 123
TABLE 40 UNMET NEEDS OF VARIOUS END-USE INDUSTRIES IN AUTOINJECTORS MARKET 123
TABLE 41 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 125
TABLE 42 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 125
TABLE 43 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 126
TABLE 44 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 127
TABLE 45 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 127
TABLE 46 AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132
TABLE 47 AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 132
TABLE 48 COMMERCIALLY AVAILABLE FINISHED FORMULATION AUTOINJECTORS 133
TABLE 49 FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 50 COMMERCIALLY AVAILABLE AUTOINJECTOR DEVICES 134
TABLE 51 AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 52 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 137
TABLE 53 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 137
TABLE 54 FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 137
TABLE 55 FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (THOUSAND UNITS) 138
TABLE 56 COMMERCIALLY AVAILABLE DISPOSABLE AUTOINJECTORS 138
TABLE 57 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 58 DISPOSABLE FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 59 COMMERCIALLY AVAILABLE REUSABLE AUTOINJECTORS 141
TABLE 60 REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 61 REUSABLE FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 62 AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 145
TABLE 63 AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (THOUSAND UNITS) 145
TABLE 64 FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 146
TABLE 65 FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 146
TABLE 66 COMMERCIALLY AVAILABLE MECHANICAL (SPRING-BASED) AUTOINJECTORS 147
TABLE 67 MECHANICAL (SPRING-BASED) AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 68 MECHANICAL (SPRING-BASED) FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 69 COMMERCIALLY AVAILABLE ELECTRONIC AUTOINJECTORS 149
TABLE 70 ELECTRONIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 71 ELECTRONIC FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 72 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 153
TABLE 73 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (THOUSAND UNITS) 153
TABLE 74 FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 153
TABLE 75 FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 154
TABLE 76 COMMERCIALLY AVAILABLE AUTOINJECTORS USING THE SUBCUTANEOUS ROUTE 155
TABLE 77 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ADMINISTRATION,
BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 78 FINISHED FORMULATION AUTOINJECTORS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 79 COMMERCIALLY AVAILABLE AUTOINJECTORS USING THE INTRAMUSCULAR ROUTE 157
TABLE 80 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 81 FINISHED FORMULATION AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 82 AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 161
TABLE 83 AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 161
TABLE 84 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR RHEUMATOID ARTHRITIS 162
TABLE 85 AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 86 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR DIABETES 164
TABLE 87 AUTOINJECTORS MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 88 AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY COUNTRY,
2024–2031 (USD MILLION) 166
TABLE 89 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR MULTIPLE SCLEROSIS 167
TABLE 90 AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 91 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR OBESITY 169
TABLE 92 AUTOINJECTORS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 93 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR OTHER THERAPY AREAS 170
TABLE 94 AUTOINJECTORS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 95 AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 173
TABLE 96 AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (THOUSAND UNITS) 173
TABLE 97 FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 174
TABLE 98 FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (THOUSAND UNITS) 174
TABLE 99 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR BIOLOGICS 175
TABLE 100 AUTOINJECTOR DEVICES MARKET FOR BIOLOGICS, BY COUNTRY,
2024–2031 (USD MILLION) 175
TABLE 101 FINISHED FORMULATION AUTOINJECTORS MARKET FOR BIOLOGICS,
BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 102 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR BIOSIMILARS 177
TABLE 103 AUTOINJECTOR DEVICES MARKET FOR BIOSIMILARS, BY COUNTRY,
2024–2031 (USD MILLION) 178
TABLE 104 FINISHED FORMULATION AUTOINJECTORS MARKET FOR BIOSIMILARS,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 105 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR SMALL MOLECULES 180
TABLE 106 AUTOINJECTOR DEVICES MARKET FOR SMALL MOLECULES, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 107 FINISHED FORMULATION AUTOINJECTORS MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 108 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 184
TABLE 109 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 184
TABLE 110 FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 184
TABLE 111 FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (THOUSAND UNITS) 185
TABLE 112 COMMERCIALLY AVAILABLE AUTOINJECTORS: UP TO 3ML 186
TABLE 113 UP TO 3ML AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 114 UP TO 3ML FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 115 COMMERCIALLY AVAILABLE AUTOINJECTORS: ABOVE 3ML 188
TABLE 116 ABOVE 3ML AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 117 ABOVE 3ML FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 118 AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 192
TABLE 119 AUTOINJECTOR DEVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 120 AUTOINJECTOR DEVICES MARKET FOR CDMOS, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 121 FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 195
TABLE 122 FINISHED FORMULATION AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 123 FINISHED FORMULATION AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 124 FINISHED FORMULATION AUTOINJECTORS MARKET FOR AMBULATORY CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 125 FINISHED FORMULATION AUTOINJECTORS MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 126 AUTOINJECTOR DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 127 FINISHED FORMULATION AUTOINJECTORS MARKET, BY REGION,
2024–2031 (USD MILLION) 202
TABLE 128 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 205
TABLE 129 NORTH AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 130 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 206
TABLE 131 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (THOUSAND UNITS) 206
TABLE 132 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 207
TABLE 133 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 207
TABLE 134 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 207
TABLE 135 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 208
TABLE 136 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 208
TABLE 137 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 208
TABLE 138 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (THOUSAND UNITS) 209
TABLE 139 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 209
TABLE 140 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 141 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 210
TABLE 142 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 210
TABLE 143 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 210
TABLE 144 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 211
TABLE 145 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 211
TABLE 146 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 212
TABLE 147 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 212
TABLE 148 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 212
TABLE 149 AUTOINJECTORS APPROVED BY US FDA, 2018–2024 213
TABLE 150 US: KEY MACROINDICATORS 214
TABLE 151 US: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 152 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 214
TABLE 153 US: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 215
TABLE 154 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 215
TABLE 155 US: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 215
TABLE 156 US: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 216
TABLE 157 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 216
TABLE 158 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 216
TABLE 159 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 217
TABLE 160 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 217
TABLE 161 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA,
2024–2031 (USD MILLION) 217
TABLE 162 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 218
TABLE 163 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 218
TABLE 164 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 218
TABLE 165 CANADA: KEY MACROINDICATORS 219
TABLE 166 CANADA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 167 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 220
TABLE 168 CANADA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 220
TABLE 169 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 220
TABLE 170 CANADA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 221
TABLE 171 CANADA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 221
TABLE 172 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 221
TABLE 173 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 222
TABLE 174 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 222
TABLE 175 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 222
TABLE 176 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 223
TABLE 177 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 223
TABLE 178 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 223
TABLE 179 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 224
TABLE 180 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 225
TABLE 181 EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 182 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 225
TABLE 183 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (THOUSAND UNITS) 226
TABLE 184 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 226
TABLE 185 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (THOUSAND UNITS) 226
TABLE 186 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 227
TABLE 187 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 227
TABLE 188 EUROPE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 227
TABLE 189 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 228
TABLE 190 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (THOUSAND UNITS) 228
TABLE 191 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 228
TABLE 192 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 193 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 229
TABLE 194 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 229
TABLE 195 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 230
TABLE 196 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 230
TABLE 197 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 231
TABLE 198 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 231
TABLE 199 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 231
TABLE 200 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 232
TABLE 201 GERMANY: KEY MACROINDICATORS 233
TABLE 202 GERMANY: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 203 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 233
TABLE 204 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 234
TABLE 205 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 234
TABLE 206 GERMANY: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 234
TABLE 207 GERMANY: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 235
TABLE 208 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 235
TABLE 209 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 235
TABLE 210 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 236
TABLE 211 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 236
TABLE 212 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 236
TABLE 213 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 237
TABLE 214 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 237
TABLE 215 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 237
TABLE 216 UK: KEY MACROINDICATORS 238
TABLE 217 UK: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 218 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 239
TABLE 219 UK: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 239
TABLE 220 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 240
TABLE 221 UK: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 240
TABLE 222 UK: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 240
TABLE 223 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 241
TABLE 224 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 241
TABLE 225 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 241
TABLE 226 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 242
TABLE 227 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA,
2024–2031 (USD MILLION) 242
TABLE 228 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 242
TABLE 229 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 243
TABLE 230 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 243
TABLE 231 FRANCE: KEY MACROINDICATORS 244
TABLE 232 FRANCE: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 233 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 244
TABLE 234 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 245
TABLE 235 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 245
TABLE 236 FRANCE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 245
TABLE 237 FRANCE: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 246
TABLE 238 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 246
TABLE 239 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 246
TABLE 240 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 247
TABLE 241 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 247
TABLE 242 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 247
TABLE 243 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 248
TABLE 244 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 248
TABLE 245 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 248
TABLE 246 ITALY: KEY MACROINDICATORS 249
TABLE 247 ITALY: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 248 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 250
TABLE 249 ITALY: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 250
TABLE 250 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 250
TABLE 251 ITALY: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 251
TABLE 252 ITALY: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 251
TABLE 253 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 251
TABLE 254 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 252
TABLE 255 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 252
TABLE 256 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 252
TABLE 257 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 253
TABLE 258 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 253
TABLE 259 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 253
TABLE 260 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 261 SPAIN: KEY MACROINDICATORS 255
TABLE 262 SPAIN: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 263 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 255
TABLE 264 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 256
TABLE 265 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 256
TABLE 266 SPAIN: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 256
TABLE 267 SPAIN: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 257
TABLE 268 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 257
TABLE 269 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 257
TABLE 270 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 258
TABLE 271 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 258
TABLE 272 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 258
TABLE 273 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 259
TABLE 274 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 259
TABLE 275 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 259
TABLE 276 NETHERLANDS: KEY MACROINDICATORS 260
TABLE 277 NETHERLANDS: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 278 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 261
TABLE 279 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 261
TABLE 280 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 261
TABLE 281 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 262
TABLE 282 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 262
TABLE 283 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 262
TABLE 284 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 263
TABLE 285 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 263
TABLE 286 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 263
TABLE 287 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 264
TABLE 288 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 264
TABLE 289 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 264
TABLE 290 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 265
TABLE 291 REST OF EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 292 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 266
TABLE 293 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 266
TABLE 294 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 266
TABLE 295 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 267
TABLE 296 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 267
TABLE 297 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 267
TABLE 298 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 268
TABLE 299 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 268
TABLE 300 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 268
TABLE 301 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 269
TABLE 302 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 269
TABLE 303 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 269
TABLE 304 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 270
TABLE 305 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 306 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 307 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 273
TABLE 308 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (THOUSAND UNITS) 274
TABLE 309 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 274
TABLE 310 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 274
TABLE 311 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 275
TABLE 312 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 275
TABLE 313 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 275
TABLE 314 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 276
TABLE 315 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD THOUSAND UNITS 276
TABLE 316 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 276
TABLE 317 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 318 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 277
TABLE 319 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 277
TABLE 320 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 278
TABLE 321 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 278
TABLE 322 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 279
TABLE 323 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 279
TABLE 324 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 280
TABLE 325 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 280
TABLE 326 JAPAN: KEY MACROINDICATORS 281
TABLE 327 JAPAN: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 328 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 282
TABLE 329 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 282
TABLE 330 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 282
TABLE 331 JAPAN: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 283
TABLE 332 JAPAN: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 283
TABLE 333 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 283
TABLE 334 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 284
TABLE 335 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 284
TABLE 336 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 284
TABLE 337 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 285
TABLE 338 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 285
TABLE 339 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 285
TABLE 340 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 286
TABLE 341 CHINA: KEY MACROINDICATORS 286
TABLE 342 CHINA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 343 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 287
TABLE 344 CHINA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 287
TABLE 345 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 288
TABLE 346 CHINA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 288
TABLE 347 CHINA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 288
TABLE 348 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 289
TABLE 349 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 289
TABLE 350 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 289
TABLE 351 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 290
TABLE 352 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 290
TABLE 353 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 290
TABLE 354 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 291
TABLE 355 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 291
TABLE 356 INDIA: KEY MACROINDICATORS 292
TABLE 357 INDIA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 358 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 292
TABLE 359 INDIA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 293
TABLE 360 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 293
TABLE 361 INDIA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 293
TABLE 362 INDIA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 294
TABLE 363 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 294
TABLE 364 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 294
TABLE 365 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 295
TABLE 366 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 295
TABLE 367 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 295
TABLE 368 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 296
TABLE 369 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 296
TABLE 370 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 296
TABLE 371 AUSTRALIA: KEY MACROINDICATORS 297
TABLE 372 AUSTRALIA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 373 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 298
TABLE 374 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 298
TABLE 375 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 298
TABLE 376 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 299
TABLE 377 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 299
TABLE 378 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 299
TABLE 379 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 300
TABLE 380 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 300
TABLE 381 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 300
TABLE 382 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 301
TABLE 383 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 301
TABLE 384 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 301
TABLE 385 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 302
TABLE 386 SOUTH KOREA: KEY MACROINDICATORS 302
TABLE 387 SOUTH KOREA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 388 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 303
TABLE 389 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 303
TABLE 390 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 304
TABLE 391 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 304
TABLE 392 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 304
TABLE 393 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 305
TABLE 394 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 305
TABLE 395 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 305
TABLE 396 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 306
TABLE 397 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 306
TABLE 398 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 306
TABLE 399 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 307
TABLE 400 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 307
TABLE 401 THAILAND: KEY MACROINDICATORS 308
TABLE 402 THAILAND: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 403 THAILAND: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 308
TABLE 404 THAILAND: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 309
TABLE 405 THAILAND: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 309
TABLE 406 THAILAND: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 309
TABLE 407 THAILAND: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 310
TABLE 408 THAILAND: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 310
TABLE 409 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 310
TABLE 410 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 311
TABLE 411 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 311
TABLE 412 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 311
TABLE 413 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 312
TABLE 414 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 312
TABLE 415 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 312
TABLE 416 VIETNAM: KEY MACROINDICATORS 313
TABLE 417 VIETNAM: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 418 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 314
TABLE 419 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 314
TABLE 420 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 314
TABLE 421 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 315
TABLE 422 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 315
TABLE 423 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 315
TABLE 424 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 316
TABLE 425 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 316
TABLE 426 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 316
TABLE 427 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 317
TABLE 428 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 317
TABLE 429 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 317
TABLE 430 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 318
TABLE 431 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE,
2024–2031 (USD MILLION) 318
TABLE 432 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 319
TABLE 433 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 319
TABLE 434 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 319
TABLE 435 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 320
TABLE 436 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 320
TABLE 437 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 320
TABLE 438 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 321
TABLE 439 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 321
TABLE 440 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 321
TABLE 441 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 322
TABLE 442 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 322
TABLE 443 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 322
TABLE 444 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 323
TABLE 445 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 324
TABLE 446 LATIN AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 447 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 324
TABLE 448 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (THOUSAND UNITS) 325
TABLE 449 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 325
TABLE 450 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 325
TABLE 451 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 326
TABLE 452 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 326
TABLE 453 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 326
TABLE 454 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 327
TABLE 455 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (THOUSAND UNITS) 327
TABLE 456 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 327
TABLE 457 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 328
TABLE 458 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 328
TABLE 459 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 328
TABLE 460 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 329
TABLE 461 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 329
TABLE 462 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 330
TABLE 463 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 330
TABLE 464 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 330
TABLE 465 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 331
TABLE 466 BRAZIL: MACROECONOMIC INDICATORS 331
TABLE 467 BRAZIL: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 468 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 332
TABLE 469 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 332
TABLE 470 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 333
TABLE 471 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 333
TABLE 472 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 333
TABLE 473 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 334
TABLE 474 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 334
TABLE 475 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 334
TABLE 476 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 335
TABLE 477 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 335
TABLE 478 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 335
TABLE 479 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 336
TABLE 480 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 336
TABLE 481 MEXICO: MACROECONOMIC INDICATORS 337
TABLE 482 MEXICO: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 483 MEXICO: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 337
TABLE 484 MEXICO: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 338
TABLE 485 MEXICO: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 338
TABLE 486 MEXICO: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 338
TABLE 487 MEXICO: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 339
TABLE 488 MEXICO: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 339
TABLE 489 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 339
TABLE 490 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 340
TABLE 491 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 340
TABLE 492 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 340
TABLE 493 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 341
TABLE 494 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 341
TABLE 495 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 341
TABLE 496 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TYPE,
2024–2031 (USD MILLION) 342
TABLE 497 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 342
TABLE 498 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 343
TABLE 499 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 343
TABLE 500 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 343
TABLE 501 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 344
TABLE 502 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 344
TABLE 503 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 344
TABLE 504 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 345
TABLE 505 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 345
TABLE 506 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 345
TABLE 507 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 346
TABLE 508 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 346
TABLE 509 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 346
TABLE 510 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 348
TABLE 511 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 348
TABLE 512 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 348
TABLE 513 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (THOUSAND UNITS) 349
TABLE 514 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 349
TABLE 515 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 349
TABLE 516 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 350
TABLE 517 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 350
TABLE 518 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 350
TABLE 519 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 351
TABLE 520 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (THOUSAND UNITS) 351
TABLE 521 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 351
TABLE 522 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY REGION, 2024–2031 (USD MILLION) 352
TABLE 523 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 352
TABLE 524 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 352
TABLE 525 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 353
TABLE 526 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 353
TABLE 527 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 354
TABLE 528 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 354
TABLE 529 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 354
TABLE 530 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 355
TABLE 531 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 356
TABLE 532 GCC COUNTRIES: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 533 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 356
TABLE 534 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 357
TABLE 535 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 357
TABLE 536 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 357
TABLE 537 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 358
TABLE 538 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 358
TABLE 539 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 358
TABLE 540 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 359
TABLE 541 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 359
TABLE 542 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 359
TABLE 543 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 360
TABLE 544 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 360
TABLE 545 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 360
TABLE 546 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 361
TABLE 547 KSA: KEY MACROINDICATORS 362
TABLE 548 KSA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 549 KSA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 362
TABLE 550 KSA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 363
TABLE 551 KSA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 363
TABLE 552 KSA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 363
TABLE 553 KSA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 364
TABLE 554 KSA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 364
TABLE 555 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 364
TABLE 556 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 365
TABLE 557 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 365
TABLE 558 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 365
TABLE 559 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 366
TABLE 560 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 366
TABLE 561 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 366
TABLE 562 UNITED ARAB EMIRATES: KEY MACROINDICATORS 367
TABLE 563 UNITED ARAB EMIRATES: AUTOINJECTORS MARKET, BY TYPE,
2024–2031 (USD MILLION) 367
TABLE 564 UAE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 368
TABLE 565 UAE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM,
2024–2031 (USD MILLION) 368
TABLE 566 UAE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 368
TABLE 567 UAE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 369
TABLE 568 UAE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 369
TABLE 569 UAE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 369
TABLE 570 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE,
2024–2031 (USD MILLION) 370
TABLE 571 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 370
TABLE 572 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 370
TABLE 573 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 371
TABLE 574 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 371
TABLE 575 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME,
2024–2031 (USD MILLION) 371
TABLE 576 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER,
2024–2031 (USD MILLION) 372
TABLE 577 OTHER GCC COUNTRIES: AUTOINJECTORS MARKET, BY TYPE,
2024–2031 (USD MILLION) 372
TABLE 578 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE,
2024–2031 (USD MILLION) 373
TABLE 579 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 373
TABLE 580 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 373
TABLE 581 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE,
2024–2031 (USD MILLION) 374
TABLE 582 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY VOLUME,
2024–2031 (USD MILLION) 374
TABLE 583 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 374
TABLE 584 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY USAGE, 2024–2031 (USD MILLION) 375
TABLE 585 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 375
TABLE 586 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 375
TABLE 587 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY THERAPY AREA, 2024–2031 (USD MILLION) 376
TABLE 588 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 376
TABLE 589 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 376
TABLE 590 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET,
BY END USER, 2024–2031 (USD MILLION) 377
TABLE 591 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TYPE,
2024–2031 (USD MILLION) 378
TABLE 592 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY USAGE, 2024–2031 (USD MILLION) 378
TABLE 593 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 378
TABLE 594 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 379
TABLE 595 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY DRUG TYPE, 2024–2031 (USD MILLION) 379
TABLE 596 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY VOLUME, 2024–2031 (USD MILLION) 379
TABLE 597 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 380
TABLE 598 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 380
TABLE 599 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 380
TABLE 600 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 381
TABLE 601 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 381
TABLE 602 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 381
TABLE 603 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 382
TABLE 604 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 382
TABLE 605 OVERVIEW OF STRATEGIES DEPLOYED BY KEY AUTOINJECTOR DEVICE MANUFACTURING COMPANIES, JANUARY 2022–FEBRUARY 2026 384
TABLE 606 OVERVIEW OF STRATEGIES DEPLOYED BY KEY FINISHED FORMULATION AUTOINJECTORS COMPANIES, JANUARY 2022–FEBRUARY 2026 386
TABLE 607 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION 390
TABLE 608 FINISHED FORMULATION AUTOINJECTORS MARKET: DEGREE OF COMPETITION 393
TABLE 609 AUTOINJECTOR DEVICES MARKET: REGION FOOTPRINT 398
TABLE 610 AUTOINJECTOR DEVICES MARKET: USAGE FOOTPRINT 399
TABLE 611 AUTOINJECTOR DEVICES MARKET: VOLUME FOOTPRINT 400
TABLE 612 AUTOINJECTOR DEVICES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 401
TABLE 613 FINISHED FORMULATION AUTOINJECTORS MARKET: REGION FOOTPRINT 404
TABLE 614 FINISHED FORMULATION AUTOINJECTORS MARKET: USAGE FOOTPRINT 405
TABLE 615 FINISHED FORMULATION AUTOINJECTORS MARKET: VOLUME FOOTPRINT 405
TABLE 616 FINISHED FORMULATION AUTOINJECTORS MARKET: ROUTE OF
ADMINISTRATION FOOTPRINT 406
TABLE 617 AUTOINJECTOR DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 408
TABLE 618 AUTOINJECTOR DEVICES MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUP/SME PLAYERS 409
TABLE 619 FINISHED FORMULATION AUTOINJECTORS MARKET: DETAILED LIST
OF KEY STARTUPS/SMES 411
TABLE 620 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 411
TABLE 621 AUTOINJECTOR DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–FEBRUARY 2026 414
TABLE 622 AUTOINJECTOR DEVICES MARKET: DEALS, JANUARY 2022–FEBRUARY 2026 415
TABLE 623 AUTOINJECTOR DEVICES MARKET: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 416
TABLE 624 FINISHED FORMULATION AUTOINJECTORS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–FEBRUARY 2026 416
TABLE 625 FINISHED FORMULATION AUTOINJECTORS MARKET: DEALS,
JANUARY 2022–FEBRUARY 2026 418
TABLE 626 FINISHED FORMULATION AUTOINJECTORS MARKET: EXPANSIONS,
JANUARY 2022–FEBRUARY 2026 418
TABLE 627 SHL MEDICAL AG: COMPANY OVERVIEW 419
TABLE 628 SHL MEDICAL AG: PRODUCTS OFFERED 419
TABLE 629 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 420
TABLE 630 SHL MEDICAL AG: DEALS, JANUARY 2021–JULY 2024 421
TABLE 631 SHL MEDICAL AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024 423
TABLE 632 YPSOMED AG: COMPANY OVERVIEW 425
TABLE 633 YPSOMED AG: PRODUCTS OFFERED 427
TABLE 634 YPSOMED AG: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 428
TABLE 635 YPSOMED AG: DEALS, JANUARY 2022–FEBRUARY 2026 428
TABLE 636 YPSOMED AG: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 430
TABLE 637 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 432
TABLE 638 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 433
TABLE 639 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS,
JANUARY 2022–FEBRUARY 2026 434
TABLE 640 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 435
TABLE 641 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 436
TABLE 642 BECTON, DICKINSON AND COMPANY (BD): DEALS,
JANUARY 2022–FEBRUARY 2026 437
TABLE 643 PHILLIPS-MEDISIZE: COMPANY OVERVIEW 439
TABLE 644 PHILLIPS-MEDISIZE: PRODUCTS OFFERED 439
TABLE 645 PHILLIPS-MEDISIZE: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 440
TABLE 646 HALOZYME, INC.: COMPANY OVERVIEW 441
TABLE 647 HALOZYME, INC.: PRODUCTS OFFERED 442
TABLE 648 OWEN MUMFORD: COMPANY OVERVIEW 443
TABLE 649 OWEN MUMFORD: PRODUCTS OFFERED 443
TABLE 650 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 444
TABLE 651 OWEN MUMFORD LTD.: DEALS, JANUARY 2022–FEBRUARY 2026 444
TABLE 652 ELI LILLY AND COMPANY: COMPANY OVERVIEW 445
TABLE 653 ELI LILLY AND COMPANY: PRODUCTS OFFERED 446
TABLE 654 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 447
TABLE 655 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–FEBRUARY 2026 448
TABLE 656 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 449
TABLE 657 ABBVIE INC.: COMPANY OVERVIEW 451
TABLE 658 ABBVIE INC.: PRODUCTS OFFERED 452
TABLE 659 ABBVIE INC: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 453
TABLE 660 ABBVIE INC.: DEALS, JANUARY 2022–FEBRUARY 2026 454
TABLE 661 SANOFI: COMPANY OVERVIEW 455
TABLE 662 SANOFI: PRODUCTS OFFERED 456
TABLE 663 SANOFI: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 457
TABLE 664 NOVO NORDISK A/S: COMPANY OVERVIEW 458
TABLE 665 NOVO NORDISK A/S: PRODUCTS OFFERED 459
TABLE 666 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 460
TABLE 667 NOVO NORDISK A/S: DEALS, JANUARY 2022–FEBRUARY 2026 461
TABLE 668 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 461
TABLE 669 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 462
TABLE 670 AMGEN INC.: COMPANY OVERVIEW 463
TABLE 671 AMGEN INC.: PRODUCTS OFFERED 464
TABLE 672 AMGEN INC.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 465
TABLE 673 AMGEN INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 466
TABLE 674 AMGEN INC.: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 466
TABLE 675 JOHNSON & JOHNSON: COMPANY OVERVIEW 467
TABLE 676 JOHNSON & JOHNSON: PRODUCTS OFFERED 468
TABLE 677 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 469
TABLE 678 JOHNSON & JOHNSON: OTHER DEVELOPMENTS,
JANUARY 2021–DECEMBER 2024 469
TABLE 679 GSK PLC: COMPANY OVERVIEW 470
TABLE 680 GSK PLC: PRODUCTS OFFERED 471
TABLE 681 GSK PLC: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 472
TABLE 682 ASTRAZENECA: COMPANY OVERVIEW 473
TABLE 683 ASTRAZENECA: PRODUCTS OFFERED 474
TABLE 684 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 475
TABLE 685 ASTRAZENECA: DEALS, JANUARY 2022–FEBRUARY 2026 475
TABLE 686 ASTRAZENECA: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 476
TABLE 687 ASTRAZENECA: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 476
TABLE 688 GERRESHEIMER AG: COMPANY OVERVIEW 477
TABLE 689 HASELMEIER GMBH: COMPANY OVERVIEW 477
TABLE 690 SMC LTD: COMPANY OVERVIEW 478
TABLE 691 KALEO, INC.: COMPANY OVERVIEW 478
TABLE 692 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW 479
TABLE 693 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW 480
TABLE 694 CROSSJECT: COMPANY OVERVIEW 481
TABLE 695 JABIL, INC.: COMPANY OVERVIEW 481
TABLE 696 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW 482
TABLE 697 MIDAS PHARMA GMBH: COMPANY OVERVIEW 482
TABLE 698 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 483
TABLE 699 WINDGAP MEDICAL, INC: COMPANY OVERVIEW 483
TABLE 700 ALTAVIZ: COMPANY OVERVIEW 484
TABLE 701 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE
FACTORS ON AUTOINJECTORS MARKET 499
TABLE 702 RISK ASSESSMENT: AUTOINJECTORS MARKET 503

LIST OF FIGURES

FIGURE 1 AUTOINJECTORS MARKET: SEGMENTS CONSIDERED 49
FIGURE 2 AUTOINJECTORS MARKET: YEARS CONSIDERED 51
FIGURE 3 MARKET SCENARIO 54
FIGURE 4 AUTOINJECTOR DEVICES MARKET, 2024–2031 55
FIGURE 5 FINISHED FORMULATION AUTOINJECTORS MARKET, 2024–2031 55
FIGURE 6 AUTOINJECTOR DEVICES: MAJOR STRATEGIES ADOPTED
BY KEY MARKET PLAYERS, 2022–2025 56
FIGURE 7 FINISHED FORMULATIONS: MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2022–2025 57
FIGURE 8 DISRUPTIONS INFLUENCING GROWTH OF AUTOINJECTORS MARKET 58
FIGURE 9 HIGH-GROWTH SEGMENTS IN AUTOINJECTOR DEVICES MARKET, 2026–2031 58
FIGURE 10 HIGH-GROWTH SEGMENTS IN FINISHED FORMULATIONS MARKET, 2026–2031 59
FIGURE 11 DEVICES: ASIA PACIFIC TO REGISTER HIGHEST CAGR, IN TERMS OF VALUE, DURING FORECAST PERIOD 60
FIGURE 12 FINISHED FORMULATIONS: ASIA PACIFIC TO REGISTER HIGHEST CAGR, IN TERMS OF VALUE, DURING FORECAST PERIOD 61
FIGURE 13 GROWING INCIDENCE OF CHRONIC DISEASES AND PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH 62
FIGURE 14 DISPOSABLE AUTOINJECTORS SEGMENT IN ASIA PACIFIC ACCOUNTED FOR LARGEST SHARE IN 2025 63
FIGURE 15 MECHANICAL AUTOINJECTORS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR THE LARGEST SHARE IN 2025 64
FIGURE 16 CHINA TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 65
FIGURE 17 CHINA TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 66
FIGURE 18 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 67
FIGURE 19 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 80
FIGURE 20 AUTOINJECTORS MARKET EQUIPMENT MARKET: SUPPLY CHAIN ANALYSIS 84
FIGURE 21 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 22 AUTOINJECTORS MARKET ECOSYSTEM 86
FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 95
FIGURE 24 INVESTMENT AND FUNDING SCENARIO FOR AUTOINJECTORS MARKET PLAYERS 96
FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR AUTOINJECTOR PATENTS (JANUARY 2014–MARCH 2026) 112
FIGURE 26 AUTOINJECTORS MARKET: AI USE CASES 118
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTORS 121
FIGURE 28 KEY BUYING CRITERIA FOR AUTOINJECTORS, BY END USER 122
FIGURE 29 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2025) 204
FIGURE 30 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS
MARKET SNAPSHOT (2025) 205
FIGURE 31 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2025) 271
FIGURE 32 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS
MARKET SNAPSHOT (2025) 272
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES
MARKET (2022–2025) 388
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION
AUTOINJECTORS MARKET (2023–2025) 389
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR
DEVICES MARKET (2025) 390
FIGURE 36 US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN
AUTOINJECTOR DEVICES MARKET (2025) 391
FIGURE 37 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2025) 391
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2025) 393
FIGURE 39 US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2025) 394
FIGURE 40 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2025) 394
FIGURE 41 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 396
FIGURE 42 AUTOINJECTOR DEVICES MARKET: COMPANY FOOTPRINT 397
FIGURE 43 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 403
FIGURE 44 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPANY FOOTPRINT 404
FIGURE 45 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 407
FIGURE 46 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 410
FIGURE 47 EV/EBITDA OF KEY VENDORS 412
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 412
FIGURE 49 AUTOINJECTOR DEVICES MARKET: BRAND COMPARATIVE ANALYSIS 413
FIGURE 50 YPSOMED AG: COMPANY SNAPSHOT (2025) 426
FIGURE 51 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2025) 433
FIGURE 52 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 436
FIGURE 53 HALOZYME, INC.: COMPANY SNAPSHOT (2025) 442
FIGURE 54 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 446
FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2025) 452
FIGURE 56 SANOFI: COMPANY SNAPSHOT (2025) 456
FIGURE 57 NOVO NORDISK A/S: COMPANY SNAPSHOT (2025) 459
FIGURE 58 AMGEN INC.: COMPANY SNAPSHOT (2025) 464
FIGURE 59 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2025) 468
FIGURE 60 GSK PLC: COMPANY SNAPSHOT (2025) 471
FIGURE 61 ASTRAZENECA: COMPANY SNAPSHOT (2025) 474
FIGURE 62 AUTOINJECTORS MARKET: RESEARCH DESIGN 485
FIGURE 63 PRIMARY SOURCES 488
FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION (SUPPLY SIDE) 489
FIGURE 65 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION (DEMAND SIDE) 490
FIGURE 66 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE
AND DEMAND-SIDE PARTICIPANTS 490
FIGURE 67 AUTOINJECTOR DEVICES MARKET: SUPPLY-SIDE ANALYSIS
(BOTTOM-UP APPROACH) 491
FIGURE 68 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES:
REVENUE SHARE ANALYSIS 492
FIGURE 69 ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS (2025) 492
FIGURE 70 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 493
FIGURE 71 MARKET SIZE ESTIMATION FOR FINISHED FORMULATIONS:
REVENUE SHARE ANALYSIS 494
FIGURE 72 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS (2025) 495
FIGURE 73 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 496
FIGURE 74 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS (2026–2031) 498
FIGURE 75 FINISHED FORMULATION AUTOINJECTORS MARKET: CAGR PROJECTIONS
(2026–2031) 498
FIGURE 76 DATA TRIANGULATION METHODOLOGY 500

---

---